← Back to Screener
NovoCure Limited Ordinary Shares (NVCR)
Price$12.67
Favorite Metrics
Price vs S&P 500 (26W)-11.19%
Price vs S&P 500 (4W)-0.95%
Market Capitalization$1.44B
All Metrics
Book Value / Share (Quarterly)$3.03
P/TBV (Annual)3.02x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)6.81%
Cash Flow / Share (Quarterly)$-0.48
Price vs S&P 500 (YTD)-5.94%
Gross Margin (TTM)74.73%
Net Profit Margin (TTM)-20.79%
EPS (TTM)$-1.22
10-Day Avg Trading Volume1.15M
EPS Excl Extra (TTM)$-1.22
Revenue Growth (5Y)5.80%
EPS (Annual)$-1.22
ROI (Annual)-25.44%
Gross Margin (Annual)74.54%
Net Profit Margin (5Y Avg)-23.48%
Cash / Share (Quarterly)$3.98
Revenue Growth QoQ (YoY)8.11%
ROA (Last FY)-16.94%
Revenue Growth TTM (YoY)8.28%
EBITD / Share (TTM)$-1.28
ROE (5Y Avg)-35.83%
Operating Margin (TTM)-23.30%
Cash Flow / Share (Annual)$-0.67
P/B Ratio4.23x
P/B Ratio (Quarterly)4.25x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)3.13x
Net Interest Coverage (TTM)-15.06x
ROA (TTM)-8.44%
EV / EBITDA (TTM)1242.63x
EPS Incl Extra (Annual)$-1.22
Current Ratio (Annual)2.90x
Quick Ratio (Quarterly)2.71x
3-Month Avg Trading Volume1.73M
52-Week Price Return-18.68%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.69
P/S Ratio (Annual)2.20x
Asset Turnover (Annual)0.81x
52-Week High$20.06
Operating Margin (5Y Avg)-24.46%
EPS Excl Extra (Annual)$-1.22
CapEx CAGR (5Y)12.22%
Tangible BV CAGR (5Y)31.18%
26-Week Price Return-4.31%
Quick Ratio (Annual)2.57x
13-Week Price Return-8.19%
Total Debt / Equity (Annual)0.57x
Current Ratio (Quarterly)2.90x
Enterprise Value$1,553.287
Revenue / Share Growth (5Y)5.31%
Asset Turnover (TTM)0.44x
Book Value / Share Growth (5Y)-8.26%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)4.38x
Pretax Margin (Annual)-20.79%
Cash / Share (Annual)$3.98
3-Month Return Std Dev92.53%
Gross Margin (5Y Avg)76.78%
Net Income / Employee (TTM)$-0
ROE (Last FY)-40.01%
Net Interest Coverage (Annual)-6.65x
EPS Basic Excl Extra (Annual)$-1.22
P/FCF (TTM)96.64x
Receivables Turnover (TTM)8.01x
Total Debt / Equity (Quarterly)0.57x
EPS Incl Extra (TTM)$-1.22
Receivables Turnover (Annual)8.01x
ROI (TTM)-10.88%
P/S Ratio (TTM)2.20x
Pretax Margin (5Y Avg)-21.01%
Revenue / Share (Annual)$5.88
Tangible BV / Share (Annual)$4.20
Price vs S&P 500 (52W)-53.31%
Year-to-Date Return-2.01%
5-Day Price Return12.12%
EPS Normalized (Annual)$-1.22
ROA (5Y Avg)-12.30%
Net Profit Margin (Annual)-20.79%
Month-to-Date Return16.24%
Cash Flow / Share (TTM)$-1.76
EBITD / Share (Annual)$-1.01
Operating Margin (Annual)-23.47%
LT Debt / Equity (Annual)0.57x
ROI (5Y Avg)-15.89%
LT Debt / Equity (Quarterly)0.57x
EPS Basic Excl Extra (TTM)$-1.22
P/TBV (Quarterly)3.38x
P/B Ratio (Annual)4.25x
Inventory Turnover (TTM)4.35x
Pretax Margin (TTM)-20.79%
Book Value / Share (Annual)$3.03
Price vs S&P 500 (13W)-10.57%
Beta0.74x
P/FCF (Annual)152.89x
Revenue / Share (TTM)$5.85
ROE (TTM)-27.62%
52-Week Low$9.82
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.08
4.08
4.08
4.08
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
NVCRNovoCure Limited Ordinary Shares | 2.20x | 5.80% | 74.73% | -23.30% | $12.67 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
NovoCure Ltd is an oncology company that develops and commercializes Tumor Treating Fields (TTFields) devices, a proprietary technology platform for treating solid tumors. The company's approved products, Optune Gio and Optune Lua, treat glioblastoma, non-small cell lung cancer, and pancreatic cancer, while its pipeline includes Trident, Lunar-2, Panova-3, and Metis candidates. With headquarters in the United States, NovoCure generates the majority of its revenue domestically, with additional sales from Germany, Japan, and other international markets.